Clene Nanomedicine, Inc., a Salt Lake City-based clinical-stage biopharmaceutical company, announced August 26, 2020 that it has raised $42.5 million in Series D financing. The round was led by SymBiosis II, LLC, a biotech-focused investment fund. Participants in the round include existing investors, most connected with
by Mark Tullis